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A B S T R A C T
The aim of this study was to evaluate the role ofDermatophagoides pteronyssinus (Dp) in atopic dermatitis patients, us-
ing atopy patch test (APT) with Dp (extract 1). Twenty patients (males (m) = 9, females (f) = 11, mean age = 46.0 years,
range = 19–78 years) with atopic dermatitis were involved in this study. The control group consisted of seventeen healthy
subjects (m=7, f=10, mean age = 48.3, range = 24–64 years), with no personal or family history and no signs of atopy. To-
tal IgE, specific IgE and a skin prick test were done for all subjects involved in this study. The atopy patch tests were per-
formed with Dp (extract 1) in: 3,000, 10,000, 20,000 and 30,000 biological units per ml (BU/ml) concentrations using glyc-
erol as medium. The total IgE was significantly higher in atopic dermatitis (AD) patients than in a control group with
(p<0.05). After the tests six of twenty patients (30%) had positive APT results in the last two concentrations (20,000 and
30,000 BU/ml). However, all the results were positive after 48 h (and 72 hours), while no positive results were recorded in
the control subjects. According to our study, APT with Dp1 in 20,000 BU/ml and reading time 48 h and 72 hours is to be
recommended. The results suggest that APT may detect the trigger factor (Dp) in AD patients.
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Introduction
Atopic dermatitis (AD) is a chronic, inflammatory, pri-
marily genetically determined skin disease, character-
ized by xerosis, pruritus and inflammation. Multiple
genes are involved in the allergen process1. In addition to
genetic factors, environmental factors also contribute to
the prevalence of AD2. The prevalence of AD has in-
creased during the past 20–30 years, so that its lifetime
prevalence is estimated 10–15%3. Both, allergic and non-
-allergic, triggers can results in AD. Household dust mite
(HDM), and animal dander are common aeroallergens
known to cause AD exacerbations. The atopy patch test
(APT) is a procedure which involves epicutaneous patch
test with allergens known for eliciting IgE-mediated re-
actions and the evaluation of eczematous skin lesions4.
The aim of this study is to evaluate the role of Dermato-
phagoides pteronyssinus (Dp) in AD patients, using APT
with Dp (extract 1).
Materials and Methods
Patients with AD: Twenty patients (males (m) = 9, fe-
males (f) = 11, mean age = 46.0 years, range = 19–78
years) with AD fulfilling the criteria of Hanifin and
Rajka5 were involved in this study (when in remission),
free of oral steroids and antihistamines for at least 7
days.
Control subjects: The control group consisted of 17
healthy subjects (m=7, f=10, mean age = 48.3, range =
24–46 years) with no personal or family history and no
signs of atopy.
Total IgE was measured with Imx-test (Microparticle
Enzyme Immunoassay-MEJA) Abbot Laboratories-USA
(normal value <120 IU/ml). The specific IgE (RAST) was
measured with CAP-RAST system (Pharmacia, Uppsala,
Sweden). The levels of the specific serum IgE that were
higher than >0.7 were regarded as positive.
Skin prick tests (SPT) were performed with standard-
ized extract Dp with a (concentration: 3,000 biological
units/ml, BU/ml) provided by the Institute of Immunol-
ogy, Zagreb, Croatia. Questionable skin reaction (when <
3 mm diameter) were regarded as negative.
Atopy patch tests (APTs) were performed using Dp1
of concentrations: 3,000, 10,000, 20,000 and 30,000 BU/ml
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concentrations in glycerol as a vehicle (Institute of Im-
munology, Zagreb, Croatia), and vehicle only as negative
control. Test substances were applied on the upper part
of the patients' back, on clinically uninvolved, untreated
and without tape stripping skin, with adhesive strips for
the patch test (Curatest, Lohmann-Rauscher, Rengsdorf,
Germany). SPT were done simultaneously with APT.
APTs were removed and reactions were evaluated after
48 h and 72 hours of exposure.. Grading of positive APT
reactions from +– to ++++ was mainly similar to the
criteria used in conventional contact allergy patch testing
(International Contact Dermatitis Research Group – ICDRG
rules)6.
² and Mann-Whitney's tests were used to evaluate
group differences (p<0.05).
Results
The total serum IgE levels were higher in atopic der-
matitis patients than in control subjects (p<0.05). In six
of twenty AD patients (30%) atopy patch tests were posi-
tive in the last two concentrations (20,000 and 30,000
BU/ml). Positive results were not seen in smaller concen-
trations of allergen. In the five of six atopy patch test
positive AD patients (83%) were RAST positive and SPT
positive. Only one APT positive patient was both SPT
negative and RAST negative (Table 1).
SPT results were positive in nine of twenty AD pa-
tients (45%), with seven of them (78%) RAST positive.
All the positive results were noted after 48 hours (and
72 hours). Concordance between APT positive, SPT posi-
tive and RAST positive results was noted in the AD pa-
tients. No positive results (APT, SPT and RAST) in
healthy control subjects were obtained.
Discussion
Atopic dermatitis is a genetically determined, IgE me-
diated, delayed-type hypersensitivity reaction of the skin7.
There is an increased number of evidence that T-cell re-
sponses to environmental allergens are important in the
pathogenesis of AD8,9. The household dust mite, Der-
matophagoides, has been shown to enhance symptoms of
atopic dermatitis and other atopic diseases4,10. Atopy
patch tests involves the epicutaneous application of the
intact protein allergens in diagnostic patch tests setting,
with an evaluation of the induced eczematous the skin le-
sion made after 48–72 hours11,12. Various concentrations
of allergens for atopy patch tests were used.
Two hundred fifty-three adults with AD, in remission,
were tested in seven study centers on clinically unin-
volved, unabraded back skin with 3,000 to 10,000 PNU/g
of Dp, cat dander, grass, birch and mugworth pollen al-
lergen extract in petrolatum. After SPT, RAST and de-
tailed history on aeroallergen-induced eczema flare was
obtained. Readings were done after 48 to 72 hours of ex-
posure. The percentage of clear-cut positive APT reac-
tion with Dp 1 was 40%. APT results showed significant
concordance with history, SPT and RAST for Dp, cat
dander and grass pollen. The optimal test concentration
for Dp was 7,000 PNU/g13. Darsow et al. (1996), are
fifty-seven patients divided in two groups: group I with
air-exposed pattern of atopic eczema, and group II which
did not have air-exposed pattern of atopic eczema. APT
was done with house dust mite, cat dander and grass pollen
mixture. The allergens concentrations were 500–10,000
PNU/g. The most frequently elicited positive APT reac-
tions were with dust mite (80%), and the most positive
results were in group I. The optimal allergen concentra-
tion for HDMwas 5,000 PNU/g and this rate could not be
increased significantly by doubling the allergen dosage12.
Optimal allergen concentration of 500x SPT and ex-
posure time of 48 hours is recommended by Van Vorst
Vader et al.14.
Goon et al.15, performed APT, skin prick test (SPT),
and RAST on 73 patients with atopic dermatitis and on
38 non-atopic controls. The allergens used were house
dust mite, cat dander, Bermuda grass and German cock-
roach. APT for house dust mite correlated with RAST
test, while APT for cat fur correlated with SPT.
Among our AD patients (n=20), six APT positive re-
sults (30%) were noted. Positive results were obtained
with allergen (Dp) concentrations of 20,000 and 30,000
BU/ml. Most of the APTs positive in our AD patients
were SPT positive and RAST positive. This was also ob-
served by others authors13,16,17. The frequency of positive
APT in patients with AD in the literature varied from
15% to 100%, owing to different test techniques and se-
lection of patients18. Different results were also related
to various allergen concentrations used for APT19. The
maximum of the positive test reactions was observed af-
ter 48 hours in the majority of the cases previously
published13,14,20. In our study all the results were positive
after 48 h (and 72 hours).
According to our results the optimal allergen concen-
tration Dp in APT is 20,000 BU/ml, so we recommend
this concentration with an exposure time of 48–72 h. For
APT concentration expressed in PNU/g the optimal al-
lergen dose range 5,000–7,000 is recomended21.
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TABLE 1
ATOPY PATCH TESTS, SPECIFIC IgE (RAST) AND SKIN PRICK
TESTS IN ATOPIC DERMATITIS PATIENTS
APT +
(N)
APT –
(N)
Sum
(N)
Dp (extract 1)
All patients
6 (30%) 14 (70%) 20 (100%)
Prick test +
Prick test –
5
1
4
10
9
11
RAST +
RAST –
5
1
2
12
7
13
APT +/–: positive/negative patch test reaction after 48h and/or
72 hours
RAST +/–: more/less than >0.70 kU/L of specific IgE
The reading time after 48 h and 72h is also recom-
mended by others authors12,19.
The results presented above suggest that APT may
detect the relevant trigger factor in AD patients with
higher specific quality than available tests22. The major
approach to management of AD is avoidance of triggers.
If the offending allergens can be identified on basis of the
history and the diagnostic testing, avoidance of these
would be a key for reduced flares2. Further investiga-
tions must give an answer for the role of APT in diagno-
sis of a subgroup of AD patients which flare after contact
with HDM, respectively with Dp.
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ATOPIJSKI »PATCH» TEST S DERMATOPHAGOIDES PTERONYSSINUS (Dp)
U BOLESNIKA S ATOPIJSKIM DERMATITISOM
S A @ E T A K
Cilj rada bio je procjena uloge Dermatophagoides pteronyssinus (Dp) u bolesnika s atopijskim dermatitisom (AD),
koriste}i atopijski »patch» test (APT) s Dp-om (ekstrakt 1). Dvadeset bolesnika s AD-om, (9 mu{karaca i 11 `ena, od
19–78 godina, prosje~ne dobi 46,0 godina), s AD-om uklju~eni su u studiju. Kontrolna skupina bila je sastavljena od 17
zdravih osoba (7 mu{karaca i 10 `ena, od 24–64 godina, prosje~ne dobi 48,3 godina), bez osobne i obiteljske anamneze o
atopiji te znakova iste.U svih ispitanika ura|en je: ko`ni »prick» test (SPT), ukupni IgE, specifi~ni IgE prema Dp-u i
APT sDp u koncentracijama: 3.000, 10.000, 20.000 i 30.000 biolo{kih jedinica/ml (BJ/ml) u glicerolu kao otapalu. U 6 od
20 (30%) bolesnika s AD-om APT bio je pozitivan u koncentracijama od 20.000 i 30.000 BJ/ml. Svi pozitivni testovi
o~itani su nakon 48 i 72 sata. Nisu na|eni pozitivni testovi u ~lanova kontrolne skupine. Prema na{im rezultatima
preporu~uje se koncentracija Dp-a u APT-u od 20.000 BJ/ml i o~itavanje rezultata nakon 48 i 72 sata.
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